Cargando…

Antifungal Susceptibilities of Bloodstream Isolates of Candida Species from Nine Hospitals in Korea: Application of New Antifungal Breakpoints and Relationship to Antifungal Usage

We applied the new clinical breakpoints (CBPs) of the Clinical and Laboratory Standards Institute (CLSI) to a multicenter study to determine the antifungal susceptibility of bloodstream infection (BSI) isolates of Candida species in Korea, and determined the relationship between the frequency of ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Won, Eun Jeong, Shin, Jong Hee, Choi, Min Ji, Lee, Wee Gyo, Park, Yeon-Joon, Uh, Young, Kim, Shine-Young, Lee, Mi-Kyung, Kim, Soo Hyun, Shin, Myung Geun, Suh, Soon Pal, Ryang, Dong Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338005/ https://www.ncbi.nlm.nih.gov/pubmed/25706866 http://dx.doi.org/10.1371/journal.pone.0118770

Ejemplares similares

Species Distribution and Susceptibility to Azole Antifungals of Candida Bloodstream Isolates from Eight University Hospitals in Korea
por: Lee, Jin-Sol, et al.
Publicado: (2007)

Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea
por: Jung, Sook-In, et al.
Publicado: (2012)

Breakpoints for the Classification of Anti-Candida Compounds in Antifungal Screening
por: Alves, Danielle da Nóbrega, et al.
Publicado: (2021)

Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal
por: Costa-de-Oliveira, Sofia, et al.
Publicado: (2020)

Multilocus Sequence Typing (MLST) Genotypes of Candida glabrata Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes
por: Byun, Seung A., et al.
Publicado: (2018)

Nationwide Surveillance of Antifungal Resistance of Candida Bloodstream Isolates in South Korean Hospitals: Two Year Report from Kor-GLASS
por: Won, Eun Jeong, et al.
Publicado: (2022)

Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis
por: González-Lara, María Fernanda, et al.
Publicado: (2017)

In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections
por: Maphanga, Tsidiso G., et al.
Publicado: (2022)

Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
por: Marins, Tatiana Aporta, et al.
Publicado: (2018)

146. antifungal Susceptibility Patterns of candida Parapsilosis Bloodstream Isolates in the US, 2008–2018
por: Tesini, Brenda L, et al.
Publicado: (2020)

Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong
por: Seneviratne, Chaminda J., et al.
Publicado: (2016)

Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey
por: Dagi, Hatice Turk, et al.
Publicado: (2016)

Invasive Candida parapsilosis Bloodstream Infections in Children: The Antifungal Susceptibility, Clinical Characteristics and Impacts on Outcomes
por: Wang, Yao-Sheng, et al.
Publicado: (2023)

Synergistic Antifungal Activity of Chito-Oligosaccharides and Commercial Antifungals on Biofilms of Clinical Candida Isolates
por: Ganan, Monica, et al.
Publicado: (2021)

Antifungal Activity of Select Essential Oils against Candida auris and Their Interactions with Antifungal Drugs
por: Parker, Ryan A., et al.
Publicado: (2022)

Candida Species Biofilms’ Antifungal Resistance
por: Silva, Sónia, et al.
Publicado: (2017)

In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values
por: Jang, Min Joong, et al.
Publicado: (2013)

Antifungal susceptibility testing of Candida species by flow cytometry.
por: Lee, W., et al.
Publicado: (1999)

Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections
por: Rezazadeh, Elham, et al.
Publicado: (2016)

Quantitative and Qualitative Analysis of the Antifungal Activity of Allicin Alone and in Combination with Antifungal Drugs
por: Kim, Young-Sun, et al.
Publicado: (2012)

In Vitro Antifungal Activity of Equol against Candida albicans
por: Lee, Jeong Ah, et al.
Publicado: (2010)

Incidence and Antifungal Susceptibility of Candida Albicans Infections
por: UNGUREANU, A., et al.
Publicado: (2016)

Antifungal Resistance in Candida auris: Molecular Determinants
por: Frías-De-León, María Guadalupe, et al.
Publicado: (2020)

Identification and Elimination of Antifungal Tolerance in Candida auris
por: Rasouli Koohi, Samira, et al.
Publicado: (2023)

Stewardship-Guided T2Candida Testing Shortens Time to Antifungal Treatment and Reduces Antifungal Usage Among Medical Intensive Care Unit Patients With Septic Shock
por: O’Donnell, Matthew, et al.
Publicado: (2023)

Impact of brief exposure to antifungal agents on the post-antifungal effect and hemolysin activity of oral Candida albicans
por: ELLEPOLA, Arjuna Nishantha, et al.
Publicado: (2015)

In vitro antifungal susceptibilities of six antifungal drugs against clinical Candida glabrata isolates according to EUCAST
por: Fatahinia, Mahnaz, et al.
Publicado: (2020)

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021)

Synergistic Antifungal Activity of Synthetic Peptides and Antifungal Drugs against Candida albicans and C. parapsilosis Biofilms
por: Bezerra, Leandro P., et al.
Publicado: (2022)

Natural Compounds with Antifungal Properties against Candida albicans and Identification of Hinokitiol as a Promising Antifungal Drug
por: Camaioni, Louis, et al.
Publicado: (2023)

Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers
por: da Matta, Daniel Archimedes, et al.
Publicado: (2017)

Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018
por: Won, Eun Jeong, et al.
Publicado: (2021)

Antifungal effect of 4-arylthiosemicarbazides against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives
por: Siwek, Agata, et al.
Publicado: (2012)

Antifungal and Anti-Inflammatory Activities of PS1-2 Peptide against Fluconazole-Resistant Candida albicans
por: Lee, Jong-Kook, et al.
Publicado: (2022)

407. Changes in the Utilization Patterns of Antifungal Agents, Medical cost, and Clinical Outcomes of Candidemia by Healthcare Benefit Expansion to Include Newer Antifungal Agents
por: Choi, Heun, et al.
Publicado: (2018)

Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis
por: Song, You Bum, et al.
Publicado: (2015)

Antifungal Susceptibility Tests and the cyp51 Mutant Strains among Clinical Aspergillus fumigatus Isolates from Korean Multicenters
por: Won, Eun Jeong, et al.
Publicado: (2020)

Antifungal activity of local anesthetics against Candida species.
por: Pina-Vaz, C, et al.
Publicado: (2000)

Candida glabrata susceptibility to antifungals and phagocytosis is modulated by acetate
por: Mota, Sandra, et al.
Publicado: (2015)

Biguanides enhance antifungal activity against Candida glabrata
por: Xu, Shuying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_22sbi25btil39a4vi1n2ortqon